AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 16 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A licensed human anthrax vaccine (Anthrax Vaccine Adsorbed [AVA]) protects 80%-100% of rabbits and rhesus macaques from challenge with Bacillus anthracis, say researchers at the U.S. Army Medical Research Institute of Infectious Diseases.
AVA's efficacy is not as reliable in guinea pigs, however, reported P.F. Fellows and associates.
They investigated AVA against spore challenge by B. anthracis isolates of diverse geographical origin, starting with 33 isolates given intramuscularly to guinea pigs. The guinea pigs had been vaccinated at 0 and 4 weeks and challenged with B. anthracis at 10 weeks. Survival among the various groups ranged from 6% to 100%.
The researchers then infected AVA-vaccinated rabbits by aerosol challenge with six of the strains that had proved most virulent in guinea pigs. This time, the protection rate was more impressive: 100% protection in four groups and 90% protection in the remaining two.
Finally, Fellows and coworkers challenged rhesus macaques with the two strains that were most virulent in rabbits, also by the aerosol route.
Protection from these two isolates was 80% and 100% ("Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis ...
Source: HighBeam Research, Vaccine Effective Against Virulent Bacterial Strains In Rabbits,...